Bioverativ
| Company type | Subsidiary |
|---|---|
| Nasdaq: BIVV | |
| Industry | Biotechnology |
| Founded | 2016 (Spun off from Biogen) |
Key people | John G. Cox (CEO) |
| Products | Alprolix, Eloctate |
Number of employees | 400 |
| Parent | Sanofi |
| Website | sanofi |
Bioverativ Inc. is an American multinational biotechnology company that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia. Bioverativ competes with Baxalta (acquired by Shire Plc in 2016), Pfizer and Novo Nordisk. The company traded on the NASDAQ exchange under the ticker symbol BIVV until Sanofi completed its acquisition on March 8, 2018.